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THE POTENTIAL CLINICAL AND ECONOMIC OUTCOMES OF
PHARMACOGENETIC-ORIENTED WARFARIN THERAPY IN RUSSIA
Gerasimova KV
The First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia, Moscow,
Moscow, Russia
OBJECTIVES: To evaluate the potential clinical and economic outcomes of using
genotype data to guide the management of warfarin anticoagulation therapy.
METHODS: A decision tree was designed to simulate two groups – group of stan-
dard care and genotyped group. Both groups were separated by CYP2C9 genotypes
in patients with alleles CYP2C9*2 and CYP2C9*3 and patients with genotype
CYP2C9*1*1. CYP2C9*1*1 patients were subdivided further into VKORCBB and
VKORCAA/AB types. Outcomes in each group were: major bleeding (gastrointesti-
nal and intracranial), minor bleeding (hemorrhoid, hemarthrosis, hemophtalmos
and others) and no bleeding. Direct medical costs from the Russian healthcare
system point of view were estimated. Rate of bleedings in patients with different
genotypes and relative risks of bleedings in pharmacogenetic-oriented approach
were obtained from the literature. Sensitivity analysis to key parameters was
performed. RESULTS: In the basic scenario costs of the standard treatment were
higher than in pharmacogenetics-oriented group: 8545 rubles (USD305) and 6806
rubles (USD243) for 1 patient per year respectively. Sensitivity analysis showed that
the model is sensitive to the price of pharmacogenetic test only: the pharmacoge-
netic approach remains cost-saving until the test costs less than 2600 rubles
(USD93). CONCLUSIONS: In the Russian health care system, pharmacogenetic-
oriented warfarin therapy is cost saving if the price of pharmacogenetic test does
not exceed 2600 rubles (USD93).
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CLINICO-ECONOMIC EVALUATION OF COMPLEX CARDIOVASCULAR THERAPY
WITH MAGNESIUM OROTATE IN PATIENTS WITH CHRONIC HEART FAILURE
VERSUS STANDARD THERAPY IN UKRAINE
Iakovlieva L, Kyrychenko O, Mishchenko O
National University of Pharmacy, Kharkiv, Ukraine
OBJECTIVES: To evaluate the profitability of the complex cardiovascular therapy
with magnesium orotate in patients with chronic heart failure (CHF) IV functional
class (NYHA IV).METHODS:Cost-effectiveness evaluation of 2 treatment strategies
was performed using the modeling decision tree. Data from various sources: the
results of two clinical trials (Stepura O.B., Martynow A.I., 2009; Libis R.A. et al, 1999)
and National standard of treatment of patients with CHF FC IV were used in the
modeling. Cost-effectiveness ratio was evaluated in accordance with the threshold
willingness to pay for improving health achievement. The analysis of the impact of
the investigated treatment strategies on the budget, taking into account the lost
productivity was conducted. RESULTS: The inclusion of magnesium orotate in the
CHF standard therapy improves the health (NNT was 1 / 0, 24  4), it gives an
additional 0,14 QALYs and requires additional costs. Only direct medical costs were
included in the cost value. Incremental cost-effectiveness ratio was 1517,82 $ / add.
QALY. It is less than GDP per capita (current threshold willingness to pay), i.e.
cardiovascular therapy with magnesium orotate is cost effective. However, taking
into account the financial capacity of the health system in Ukraine, in real practice
such costs for achieve better health are less acceptable than the costs of standard
therapy. Indirect costs (lost productivity) during 2 years in the application of stan-
dard therapy with magnesium orotate were less than indirect costs in application
only standard therapy. Saving money - 606,7 $ per patient. CONCLUSIONS: Thus
the inclusion of magnesium orotate in the standard therapy in patients with CHF is
cost effective. High direct costs are compensated due in indirect costs savings.
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OBJECTIVES: Salt consumption in Hungary is high in international comparison, the
average salt intake is 17,28g per day in men and 12,05g in women. Our aim was to
study the cost-effectiveness of the salt intake reduction program run by the Hun-
garian National Institute for Food and Nutrition Science. METHODS: We built a
cohort simulation Markov-model. The health benefit achieved by reduced salt in-
take was calculated for the 40-60 year old Hungarian population in 7 health states:
healthy, hypertension, acute- and post AMI and stroke, death The transitional
probabilities were calculated from national and international publications. We
used the data of National Health Found and expert estimations to define the costs
of interventions and health states. The efficacy was modeled with the use of data
from the literature. It was assumed that 3g salt reduction results in 5Hgmm decline
in systolic blood pressure (SBP) and 1Hgmm SBP lowering will reduce the preva-
lence of the hypertension with 1%. A discount rate of 5% was applied. RESULTS: If
a public health program could reduce the salt intake to 10g/day/capita at in 5 years
by 31 USD PPP/capita/year investment, then the ICER would be 4090.5 USD PPP
(1USD PPP128.92 HUF). In this scenario the lifelong risk of AMI and stroke would
decrease with 0.0034The incremental cost of the intervention is 27.15 USD PPP, and
the QALY win is 0.0066. CONCLUSIONS: An effective public health program to
reduce salt intake would be cost-effective in Hungary.
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SETTINGS LOWERS HEALTH CARE COSTS: THE MEDCO-MAYO WARFARIN
EFFECTIVENESS STUDY
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OBJECTIVES: To measure the comparative direct medical care costs between inci-
dent warfarin patients who did or did not experience genotyping to guide dosing.
METHODS: We reanalyzed the previously published MM-WES in which we dem-
onstrated that genotyping reduces the risk of hospitalization for bleeding and
thromboembolism in patients who initiate warfarin treatment in typical outpa-
tient practice settings. We used a cost consequence analysis to estimate the
6-month costs and consequences of warfarin genotyping. The intervention group
(IG) comprised 896 patients and a comparison group was constructed from 2688
historical controls (HC). The direct medical care costs were estimated for inpatient,
office visits and laboratory utilization (including cost of genotyping) and summed
to a total cost per patient. A boot-strapping method was performed to estimate
confidence limits around the difference in mean cost per patient to assess statis-
tical significance. RESULTS: Over the 6-month monitoring period, the all cause–
related per patient costs for the genotyped IG patient was $4127 compared to $5040
for HC. The all-cause difference of -$913 per patient reached statistical significance,
95% CI (-$895, -$930). Various subgroup analyses including warfarin-related costs
will be presented. CONCLUSIONS: Our analysis suggests that providing results of
warfarin genotyping to treating physicians in typical outpatient settings produces
cost-savings within six months of initiating warfarin therapy. These estimates are
likely conservative as they do not include ancillary costs such as rehabilitation or
indirect costs, nor do they estimate costs beyond six months.
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ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CARDIOVASCULAR
DISEASES IN MILD HYPERTENSION: A SCENARIO ANALYSIS FOR THE
NETHERLANDS
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OBJECTIVES: According to current Dutch guidelines, antihypertensive treatment
for patients with mild hypertension is recommended if the 10-year fatal cardiovas-
cular disease (CVD) risk exceeds 10% or if accompanying risk factors are present.
Recent evidence suggests that lifelong CVD risk estimates might be more informa-
tive than 10-year risk estimates. The aim of this study was to estimate the eco-
nomic impact and influence on CVD risk of blood pressure (BP) reduction, in pa-
tients ineligible for treatment according to guidelines. METHODS: A Markov model
was developed to assess the lifetime costs and health benefits of BP reduction with
hydrochlorothiazide (HCT) or HCT plus losartan. Patients had mild hypertension
and low 10-year CVD risk. The SCORE risk estimates were modified to predict fatal
and non-fatal events over a lifelong time horizon. We analysed scenarios for dif-
ferent age groups, gender and reductions in BP. Costs and health effects were
discounted at 4.0% and 1.5%, respectively; a Dutch healthcare perspective was
used.RESULTS:A total of 48 different scenarios were modeled. Minor BP reductions
were potentially not cost-effective in young women treated with HCT (€59,000 per
life-year gained (LYG)), whereas potential cost-effectiveness was observed in a
comparable male population (€12,000 per LYG). BP reduction was, generally, found
to be more cost-effective in men, in older subjects and for larger BP reductions (up
to cost-saving results). Results for HCT plus losartan were comparable.
CONCLUSIONS: In patients ineligible for antihypertensive treatment according to
current Dutch guidelines, reducing BP, nonetheless, resulted in clinical benefits for
several patient populations. BP reduction was found to be potentially cost-effective
in males for all age groups and even cost-saving in older ages, whereas for females
it was less favorable. This, together with recent decreases in drug prices, should
trigger further discussion on antihypertensive treatment in patients with low 10-
year fatal CVD risk.
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor plus acetylsalicylic acid (ASA) compared
with clopidogrel/ASA significantly reduced the rate of myocardial infarction (MI),
stroke, or death from vascular causes without a significant increase in the rate of
overall major bleedings. The present study evaluates the long-term cost-effective-
ness of treating patients with ticagrelor in Germany from the perspective of the
Statutory Health Insurance (SHI). METHODS: : A two-part decision-analytic model,
comprising a decision tree approach for the first year followed by a long-term
Markov model, was constructed to estimate lifetime costs and life year gained
(LYG) of treating ACS patients for one year with ticagrelor/ASA compared with
clopidogrel/ASA. Data for the first year were derived from the PLATO trial. For the
long-term model the German lifetable from the cause-of-death-statistics and se-
lected conservative assumptions were utilized to extrapolate survival conditional
on whether a non-fatal MI, a non-fatal stroke or no event occurred during the first
year. Costs were based on official tariffs (e.g. DRGs) and published literature. For the
base case daily cost of €2.99 was applied for ticagrelor. Daily cost for clopidogrel was
applied in a range from €0.38 (lowest generic) to €2.44 (Plavix) with an average
generic cost of €0.68 (base case). Extensive probabilistic, uni- and multivariate sen-
sitivity analyses were performed. RESULTS: : Treatment with ticagrelor was asso-
ciated with 0.16 LYG versus clopidogrel. The cost per LYG in the base case was
€3,361. Overall the cost per LYG ranged from €-430 (dominant situation) to €4,077
compared with clopidogrel (Plavix vs. lowest generic). Results were consistent
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throughout the sensitivity analyses. CONCLUSIONS: Based on evidence from the
PLATO study, treating a broad spectrum of ACS patients with ticagrelor for one year
seems to offer a cost-effective option in the German health care setting compared
with clopidogrel.
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OBJECTIVES:We examined sponsorship of published economic evaluations of sta-
tin use for cardiovascular (CDV) prevention and evaluated whether funding is as-
sociated with study conclusions.METHODS:A systematic review was conducted in
PubMed/MEDLINE (up to June 2011) to identify cost-effectiveness analyses of statin
use for CDV prevention reporting outcomes as cost per life years gained and/or
quality-adjusted life years. The review was restricted to 6 licensed statins: simva-
statin, pravastatin, fluvastatin, lovastatin, atorvastatin and rosuvastatin. We clas-
sified study intervention data as follows: 1) comparators: statin-statin or statin-
non active drug comparisons, and 2) primary or secondary CDV prevention. We
established relationships between funding source (industry- vs. non-industry-
sponsored studies) and qualitative conclusions (favorable, unfavorable or neutral)
by means tests of differences between proportions. RESULTS: Overall, 72 studies
were included. Thirty-six studies (50%) were carried out in Europe and 31 (43%) in
North America. Fourty-seven (65%) articles compared statins versus non-active
drugs. The category of CDV prevention was distributed as follows: 46% secondary,
39% primary and 15% both. Considering funding source, 64% were industry-spon-
sored studies. For studies evaluating primary CDV prevention, industry-sponsor-
ship was much less likely to have unfavorable or neutral conclusions (0% vs. 59%;
p0.001). Conversely, these differences were not detected for studies evaluating
secondary CDV prevention (0% versus 13%; p0.212). CONCLUSIONS: Our results
suggest that sponsorship of economic evaluation of statins is associated with their
qualitative conclusions in primary CDV prevention.
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor compared with clopidogrel significantly
reduced the rate of myocardial infarction, stroke, or death from vascular causes
without a significant increase in the rate of overall major bleeding. The aim of this
analysis is to estimate long-term cost-effectiveness of treating ACS patients with
ticagrelor from a Polish health care perspective. METHODS: The model used is a
two-part decision-analytic model, comprising a one-year decision tree and a long-
term Markov model. Model estimates lifetime costs, LYGs and QALYs of treating
ACS patients for one year with ticagrelor plus ASA compared with clopidogrel plus
ASA. The model is based on the results observed in the PLATO study and populated
with the overall clinical, resource use and quality of life results from PLATO trial.
Unit costs were derived from the National Health Fund in Poland. A generic clopi-
dogrel price of 0,92 PLN per day, and a ticagrelor price of 10,85 PLN per day were
applied. Standard mortality rates for the Polish population were used. Data are
presented in PLN with exchange rate: 1,00 PLN € 0,25. RESULTS: Treatment with
ticagrelor was associated with a QALY gain of 0,11 and a LYG gain of 0,12 compared
with clopidogrel. The incremental cost of ticagrelor treatment was 2814 PLN. The
ICER per QALY gained with ticagrelor compared with clopidogrel was 25 675 PLN,
while the ICER per LYG with ticagrelor was 22 257 PLN. Probabilistic sensitivity
analysis indicates that ticagrelor treatment has a 90% probability of being cost
effective given a willingness of pay threshold of 40 000 PLN. The results are consis-
tent in all ACS subgroups. CONCLUSIONS: Based on clinical and health economic
evidence from the PLATO study, treating ACS patients with ticagrelor for one year
is cost-effective compared with clopidogrel in Polish settings.
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COST EFFECTIVENESS OF SPEECH AND LANGUAGE THERAPY FOLLOWING
STROKE
Davies (on behalf of the ACT NoW study team) LM
University of Manchester, Manchester, UK
OBJECTIVES: Communication impairment after stroke affects everyday activities
and social participation. Speech and Language therapy (SLT) has waiting lists of 6
months plus in the National Health Service (NHS), implying a high opportunity
cost. The aim was to evaluate the cost effectiveness of SLT versus attention control
(AC), at six months, for people with communication difficulties due to aphasia/
dysarthria following stroke. METHODS: The economic analysis was an integral
component of a randomised, controlled, pragmatic trial comparing SLT (n 85) and
AC (n85). The perspective was the NHS and social care, patients and families. The
time horizon was 6 months (baseline to end of scheduled follow up). Resource use
and health status (EQ-5D) were collected on all participants recruited into the trial.
Utility values were estimated from the EQ-5D and associated population tariffs.
The setting was inpatient and community/primary care in North West England;
data were collected between 2006 and 2010. Unit cost data are for 2008-2009. Re-
gression models estimated incremental or costs and outcomes for the ICER, ad-
justed for predefined covariates. Incremental costs and outcomes were boot-
strapped to derive cost effectiveness acceptability curves, net benefit statistics and
probability that SLT was cost effective. RESULTS: The net cost of SLT was £110 (95%
percentiles: -£640 to £861). The net utility was 0.01 (95% percentiles: -0.03 to
0.04). SLT is only likely to be cost effective if decision makers are willing to pay
£25,000 or more to gain a 1 point increase in utility (p0.50). The cost effectiveness
of SLT depends on the outcome measure used and the baseline severity of stroke.
CONCLUSIONS: The primary and sensitivity analyses indicated a high level of
uncertainty suggesting it is not possible to conclude whether therapy is more or
less cost effective than attention control.
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IS TREATMENT OF DEPRESSION COST EFFECTIVE IN THE MANAGEMENT OF
PEOPLE WITH CHD AND DIABETES: A SYSTEMATIC REVIEW OF THE ECONOMIC
EVIDENCE
Jeeva F, Davies LM
University of Manchester, Manchester, UK
OBJECTIVES: About 33% of patients develop depression after myocardial infarc-
tion, while 25% of patients with diabetes have depression. Patients with co-morbid
depression have lower treatment compliance and health status, increased health-
care use, social isolation and mortality. This study aimed to systematically review
current economic evidence of non-pharmacological treatment interventions for
patients with CHD or diabetes and co-morbid clinically-relevant depression.
METHODS: The electronic search strategies (conducted in MEDLINE, EMBASE, Psy-
cINFO, CINAHL, NHS EED) combined clinical search terms with terms used by the
UK National Health Service Economic Evaluation Database (NHSEED), to identify
full economic evaluations of the relevant interventions. Pre-specified screening
and inclusion criteria were used. Standardised data extraction and critical ap-
praisal (using NHSEED criteria) were conducted. RESULTS: Excluding duplicates,
1336 studies for CHD and 1281 for diabetes were screened. Four economic evalua-
tions were identified (two for diabetes and two for CHD). The studies found that the
interventions improved health status, reduced depression and were cost-effective
compared to usual care. Both CHD studies were UK-based and used home-based
cognitive behavioural programmes. The net costs were -£42 to £2, the net QALY
gains were 0.006 to 0.009. The diabetes studies were based on US-based and used
stepped collaborative care programmes delivered by specialised nurses. The net
costs were -$1378 to $216, the net gains in depression free days were 53 to 115.
CONCLUSIONS: The review highlighted the paucity of evidence in this area and
associated uncertainty. Four small studies indicated the potential of psychological
interventions to improve the quality of life, reduce depression and be cost-effective
compared to usual care. Robust and well-designed economic evaluations of non-
pharmacological treatment interventions for patients with co-morbid depression
are needed. An economic model is being developed to synthesise data from various
sources to explore this further.
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OBJECTIVES: To estimate the cost-effectiveness of closing the statin ‘treatment
gap’ in the secondary prevention of coronary artery disease (CAD) in Australia.
METHODS:We developed a decision-analysis Markov model with yearly cycles and
the following health states: ‘Alive’ and ‘Dead’. Using data from the Australian
Reduction of Atherothrombosis for Continued Health (REACH) registry, the model
compared current statin coverage (82%) in the secondary prevention of CAD (‘Cur-
rent’ group) with a hypothetical situation of 100% coverage (‘Improved’ group). The
18% gap was filled with use of generic statins. Data from a recent meta-analysis
were used to estimate the benefits of statin use in terms of reducing recurrent
cardiovascular events and death. Government-reimbursement data from 2011 was
used to calculate direct healthcare costs. The cost of the intervention to improve
statin coverage was assumed to be $250 per person. Years of life lived and costs
were discounted at 5% annually. RESULTS: Among the 2058 subjects in the ‘Cur-
rent’ group, the model estimated that there would be 106 non-fatal myocardial
infractions, 68 non-fatal strokes and 275 deaths over five years. In the ‘Improved’
group, within which all subjects took statins, the corresponding numbers were 101,
65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively.
Over the five years, there would be 0.018 life years gained (discounted) at a net cost
of AUD $546 (discounted) per person. These equated to an incremental cost-effec-
tiveness ratio (ICER) of AUD $29,717 per life year gained. CONCLUSIONS: The re-
sults suggest that for patients with CAD, maximizing coverage with statins, in line
with evidence-based recommendations, represents a cost-effective means of sec-
ondary prevention.
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A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH NON
STABLE ACUTE CORONARY SYNDROME IN GREECE
Kourlaba G, Fragoulakis V, Maniadakis N
National School of Public Health, Athens, Greece
OBJECTIVES: To evaluate the cost-effectiveness of one-year treatment with clopi-
dogrel plus aspirin compared to aspirin alone in patients without ST-segment el-
evation (NSTEMI) from the Greek third-party-payer perspective. METHODS: A
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